- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Vitamin B3 Supplement Shows Promise in Cutting Skin Cancer Risk: JAMA

USA: A large Veterans Affairs (VA) cohort study has found that taking nicotinamide-a vitamin B3 derivative sold over the counter-significantly lowers the risk of developing skin cancer.
The protective effect was strongest when the supplement was started soon after a patient’s first skin cancer diagnosis, according to findings published in JAMA Dermatology by Dr. Kimberly F. Breglio and colleagues from the Durham VA Medical Center, North Carolina.
Nicotinamide, a form of vitamin B3, is inexpensive, widely available without prescription, and generally well tolerated. Previous small trials hinted at its protective potential, but large-scale evidence had been limited until now. This VA study adds weight to the idea that nicotinamide could be a practical chemopreventive option for patients with a history of skin cancer, especially when started early in the disease course.
The retrospective analysis explored whether regular nicotinamide supplementation could help prevent new skin cancers in a real-world population. Using Veterans Affairs electronic health records from October 1999 through December 2024, researchers reviewed data on 33,822 veterans. Among them, 12,287 patients took oral nicotinamide 500 mg twice daily for at least 30 days, while 21,479 served as matched controls who did not use the supplement. Participants were matched on factors such as age, sex, race, history of prior skin cancers, and other treatments, allowing a balanced comparison.
The study led to the following notable findings:
- Nicotinamide use was linked to a 14% lower overall risk of developing new skin cancers compared to those not taking the supplement.
- Starting the supplement soon after the first skin cancer reduced risk by 54%, showing the greatest benefit with early initiation.
- The protective effect covered both basal cell carcinoma and cutaneous squamous cell carcinoma (cSCC), with the strongest impact on cSCC.
- When nicotinamide was started after multiple skin cancers, its preventive benefit gradually declined.
- Among solid organ transplant recipients—who face higher skin cancer risk due to immunosuppressive therapy—overall risk reduction was not statistically significant.
- Early use of nicotinamide after a first cancer episode in transplant recipients still showed a notable decrease in cSCC risk, underscoring the importance of timing.
The authors emphasized that while the findings are promising, further prospective trials could help refine guidance on dosage, timing, and patient selection. Still, for many individuals at risk of recurring non-melanoma skin cancers, this easily accessible vitamin supplement may offer an effective and low-cost strategy to reduce future disease burden.
Reference:
Breglio KF, Knox KM, Hwang J, et al. Nicotinamide for Skin Cancer Chemoprevention. JAMA Dermatol. Published online September 17, 2025. doi:10.1001/jamadermatol.2025.3238
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751
Next Story